GT Biopharma, Inc. (GTBP)
USD 2.05
(-21.46%)
USD 2.05
(-21.46%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | 4000.00 | 7000.00 |
| Gross Profit | - | - | - | - | -4000.00 | -7000.00 |
| Operating Expenses | 13.57 Million | 21.25 Million | 57.51 Million | 6.76 Million | 11.45 Million | 21.55 Million |
| Selling, General and Administrative Expenses | 7.11 Million | 12.44 Million | 47.92 Million | 6.27 Million | 9.79 Million | 12.48 Million |
| Research and Development Expenses | 6.46 Million | 8.81 Million | 9.59 Million | 485 Thousand | 1.66 Million | 9.06 Million |
| Other Expenses | - | - | -242.76 Thousand | -12.59 Million | - | - |
| Cost and Expenses | 13.57 Million | 21.25 Million | 57.51 Million | 6.76 Million | 11.45 Million | 21.55 Million |
| Operating Income | -13.57 Million | -21.25 Million | -57.51 Million | -6.76 Million | -16.05 Million | -250.06 Million |
| Interest Expense | - | 8000.00 | 718 Thousand | 3.32 Million | 2.12 Million | 9.11 Million |
| Income Tax Expense | - | -381 Thousand | 680 Thousand | 3.32 Million | 2.12 Million | -228.51 Million |
| Earnings before Tax | -7.59 Million | -20.88 Million | -58.01 Million | -28.29 Million | -38.64 Million | -259.18 Million |
| Net Income | -7.59 Million | -20.5 Million | -58.69 Million | -31.61 Million | -40.77 Million | -259.18 Million |
| Earnings Per Share Basic | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 |
| Earnings Per Share Diluted | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 |
| Weighted Average Shares Outstanding | 1.34 Million | 1.06 Million | 938.52 Thousand | 146.17 Thousand | 112.79 Thousand | 2.95 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.34 Million | 1.06 Million | 938.52 Thousand | 146.17 Thousand | 112.79 Thousand | 2.95 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | 5.97 Million | - | - | -24.97 Million | -11.45 Million | -250.06 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 3.9 Million | 3.09 Million | 3.16 Million | 13.57 Million | 3.12 Million | 3.62 Million |
| Selling, General and Administrative Expenses | 2.12 Million | 2.31 Million | 1.81 Million | - | 1.75 Million | 1.52 Million |
| Research and Development Expenses | 1.78 Million | 777 Thousand | 1.35 Million | - | 1.36 Million | 2.09 Million |
| Other Expenses | -27 Thousand | 27 Thousand | - | - | - | - |
| Cost and Expenses | 3.9 Million | 3.09 Million | 3.16 Million | 13.57 Million | 3.12 Million | 3.62 Million |
| Operating Income | -3.9 Million | -3.09 Million | -3.16 Million | -13.57 Million | -3.12 Million | -3.62 Million |
| Interest Expense | - | - | - | 213 Thousand | - | 1000.00 |
| Income Tax Expense | -3.9 Million | -3.09 Million | -3168.00 | -13.57 Thousand | -3122.00 | -219 Thousand |
| Earnings before Tax | -3.71 Million | -2.26 Million | -2.96 Million | -7.59 Million | -2.41 Million | -1.99 Million |
| Net Income | -3.71 Million | -2.26 Million | -2.96 Million | -7.59 Million | -2.41 Million | -1.99 Million |
| Earnings Per Share Basic | -2.17 | -1.64 | -2.15 | - | -1.77 | -1.49 |
| Earnings Per Share Diluted | -2.17 | -1.64 | -2.15 | - | -1.77 | -1.49 |
| Weighted Average Shares Outstanding | 1.71 Million | 1.38 Million | 1.38 Million | 1.34 Million | 1.36 Million | 1.33 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.71 Million | 1.38 Million | 1.38 Million | 1.34 Million | 1.36 Million | 1.33 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -3.9 Million | -3.09 Million | -3.16 Million | - | -3.12 Million | -3.4 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
GOD
M11
MSTR
3494
BBLG
SYS1